Loss of PTEN expression is an independent predictor of favourable survival in endometrial carcinomas

British Journal of Cancer

Volumn 109, Issue 6, 2013, Pages 1703-1710

  Akiyama Abe, A ^a   Minaguchi, T ^a   Nakamura, Y ^a   Michikami, H ^a   Shikama, A ^a   Nakao, S ^a   Sakurai, M ^a   Ochi, H ^a   Onuki, M ^a   Matsumoto, K ^a   Satoh, T ^a   Oki, A ^a   Yoshikawa, H ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT ALPHA; PROTEIN KINASE B; PROTEIN P27; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DISEASE SEVERITY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; FIGO STAGE; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LOSS OF FUNCTION MUTATION; LYMPH NODE DISSECTION; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RISK FACTOR; SALPINGOOOPHORECTOMY;

ADULT; AGED; AGED, 80 AND OVER; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PTEN PHOSPHOHYDROLASE; SURVIVAL ANALYSIS;

EID: 84884589450     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.455     Document Type: Article

References (15)

1. Abe A, Minaguchi T, Ochi H, Onuki M, Okada S, Matsumoto K, Satoh T, Oki A, Yoshikawa H (2013) PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma. Hum Pathol 44(2): 199-207.
2. Baba Y, Nosho K, Shima K, Hayashi M, Meyerhardt JA, Chan AT, Giovannucci E, Fuchs CS, Ogino S (2011) Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer 117(7): 1399-1408.
3. Hutchinson JN, Jin J, Cardiff RD, Woodgett JR, Muller WJ (2004) Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res 64(9): 3171-3178.
4. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W, Moynahan ME (2009) PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15(16): 5049-5059.
5. Kodama Y, Baxter RC, Martin JL (2002) Insulin-like growth factor-I inhibits cell growth in the a549 non-small lung cancer cell line. Am J Respir Cell Mol Biol 27(3): 336-344.
6. Liu H, Radisky DC, Nelson CM, Zhang H, Fata JE, Roth RA, Bissell MJ (2006) Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. Proc Natl Acad Sci USA 103(11): 4134-4139.
7. Minaguchi T, Mori T, Kanamori Y, Matsushima M, Yoshikawa H, Taketani Y, Nakamura Y (1999) Growth suppression of human ovarian cancer cells by adenovirus-mediated transfer of the PTEN gene. Cancer Res 59(24): 6063-6067.
8. Minaguchi T, Yoshikawa H, Oda K, Ishino T, Yasugi T, Onda T, Nakagawa S, Matsumoto K, Kawana K, Taketani Y (2001) PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clin Cancer Res 7(9): 2636-2642.
9. Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, Gotlieb WH, Hoskins PJ, Ghatage P, Tonkin KS, Mackay HJ, Mazurka J, Sederias J, Ivy P, Dancey JE, Eisenhauer EA (2011) Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: A trial of the NCIC Clinical Trials Group. J Clin Oncol 29(24): 3278-3285.
10. Rahman M, Nakayama K, Rahman MT, Nakayama N, Ishikawa M, Katagiri A, Iida K, Nakayama S, Otsuki Y, Shih IeM, Miyazaki K (2012) Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. Hum Pathol 43(12): 2197-2206.
11. Risinger JI, Hayes K, Maxwell GL, Carney ME, Dodge RK, Barrett JC, Berchuck A (1998) PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 4(12): 3005-3010.
12. Salvesen HB, Stefansson I, Kretzschmar EI, Gruber P, MacDonald ND, Ryan A, Jacobs IJ, Akslen LA, Das S (2004) Significance of PTEN alterations in endometrial carcinoma: A population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol 25(6): 1615-1623.
13. Sun H, Enomoto T, Fujita M, Wada H, Yoshino K, Ozaki K, Nakamura T, Murata Y (2001) Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am J Clin Pathol 115(1): 32-38.
14. Wyszomierski SL, Yu D (2005) A knotty turnabout?: Akt1 as a metastasis suppressor. Cancer Cell 8(6): 437-439.
15. Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, Toker A (2005) Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell 20(4): 539-550.